Predicting Effective Therapy in Pancreatic Cancer (NCT03033927) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Predicting Effective Therapy in Pancreatic Cancer
United States74 participantsStarted 2017-01-24
Plain-language summary
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
* Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
* Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
* ECOG performance status 0-2.
* A minimum age of 18 years old.
Exclusion Criteria:
* Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
* Known to be HIV positive on antiretroviral therapy
* Prior organ allograft
* Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures